Theranostic Nanocarriers in Cancer: Dual Capabilities on a Single Platform
Nanotechnology in the Life Sciences, ISSN: 2523-8035, Page: 293-312
2020
- 4Citations
- 5Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
The evolution of nanotechnology has ushered in tremendous advances in the field of medicine. Nanocarriers such as liposomes, polymeric and lipidic nanoparticles, micelles, dendrimers, etc., are now used as targeted drug delivery systems that are capable of delivering the therapeutic agent to a specific site in human body. Therapeutic agents such as antimicrobials, anti-HIV, anti-Alzheimer’s, immunosuppressants, peptides, genes, as well as anti-cancer drugs, have been successfully delivered using nanocarriers for the treatment of various diseases. Early diagnosis of the disease is the key for successful management of disease. In the case of cancer, early diagnosis is critical as it can have an impact on the treatment measures and the outcomes of treatment, which affect the quality of life of the patient. The diagnostic tools used nowadays consist of various techniques such as magnetic resonance imaging, optical imaging, computed tomography, etc. These tools require diagnostic agents comprising fluorescent dyes, radioactive elements and contrast agents. These diagnostic agents are frequently administered to the patients along with chemotherapeutic agents for the detection and treatment of cancer or to monitor treatment efficiency, which generally causes toxicity in the patients. This drawback initiated a quest for development of a novel platform that is capable of simultaneous diagnosis and therapy, thereby reducing toxicity in the treatment of cancer. The outcomes of this quest are theranostic nanocarriers, which are the next generation of nanocarriers. They combine the therapeutic moieties as well as the diagnostic agents on a single platform and consist of liposomes, polymeric or metallic nanoparticles, micelles, and dendrimers as carriers. Ideally, theranostic carriers must be capable of incorporating both the diagnostic and therapeutic agents in potent quantities; they must deliver the therapeutic agent to the site of action and should be non-toxic. In this chapter, we discuss the current scenario of theranostic nanocarriers, their methods of synthesis, the diagnostic agents and therapeutic agents used in theranostic nanocarriers and their applications in the management of cancer.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85102123048&origin=inward; http://dx.doi.org/10.1007/978-3-030-41464-1_13; http://link.springer.com/10.1007/978-3-030-41464-1_13; https://dx.doi.org/10.1007/978-3-030-41464-1_13; https://link.springer.com/chapter/10.1007/978-3-030-41464-1_13
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know